Company / Revenue per Share
NEKTAR THERAPEUTICS Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$4.46
FY2025
5-year range
$0.47 / $4.46
FY2021-FY2025
Trend
+847.0%
vs FY2024
Sector context
#66 of 154
Health Care
What the data says
Revenue per Share changed +847% YoY in FY2025, a notable deviation from the 9-year average annual change of +172%.
Based on SEC 10-K filings.
4.46 in FY2025 with a 5-year CAGR of -8.0%.
Improved from $0.54 to $4.46 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +107.9%
- 5-Year CAGR
- -8.0%
- 10-Year CAGR
- -
Sector benchmark
#66 of 154 in Health CareTop 43% of 154This company $4.46 Sector average $10.35
▼
-56.9% below sector average
Key checks
Key Insights
- In FY2025, revenue per share increased 847.0% year-over-year.
- Ranks #66 out of 154 companies in the Health Care sector.
- Peak revenue per share was recorded in FY2020.
- Lowest revenue per share in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.46 | +847.0% |
| FY2024 | $0.47 | -12.9% |
| FY2023 | $0.54 | +8.9% |
| FY2022 | $0.50 | -12.3% |
| FY2021 | $0.57 | -91.6% |
| FY2020 | $6.76 | +281.3% |
| FY2019 | $1.77 | +71.0% |
| FY2018 | $1.04 | +542.6% |
| FY2017 | $0.16 | -89.1% |
| FY2016 | $1.48 | -15.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026